Global Health Strategy Intern

Join PATH and the HepC3P project at the 14th International Conference on Health and Hepatitis in Substance Users. September 28, 2026 by PATH At the 14th International Conference on Health and Hepatitis in Substance Users, PATH will highlight its work introducing innovative Hepatitis C virus prevention products and approaches, as well as roadmaps for advancing essential harm reduction services globally. Hepatitis C virus (HCV) is a viral infection that causes liver inflammation and can lead to serious liver damage. It disproportionately affects people who inject drugs (PWID) and people in prison, two groups who already face higher barriers to high-quality health services. The PATH-led, Unitaid-funded HCV Combination Prevention in PWID and Prisoners Project (HepC3P) is addressing key health access barriers in order to introduce and scale up HCV products and interventions in low- and middle-income countries (LMICs). Working with its consortia partners - Population Services International, London School of Hygiene & Tropical Medicine, and University of Bristol - as well as community groups and government stakeholders, HepC3P is accelerating uptake of HCV prevention and treatment services among PWID and people in prison. At the 14th International Conference on Health and Hepatitis in Substance Users (INHSU) 2026, PATH's HepC3P team and partners will highlight results from two groundbreaking, community-led research studies assessing the feasibility, acceptability, effectiveness, and cost of introducing long-acting depot buprenorphine and low-dead-space syringes and needles in LMICs. Path International will also share how the project is piloting integrated, person-centered approaches for PWID to access HCV services, including HIV/HCV service integration, HCV self-testing, and prison-based needle and syringe programs. In addition, Path International will present how market shaping, costing, and modeling efforts are paving the way for introduction and scale-up of effective, accessible harm reduction services globally. See below for a full schedule of HepC3P presentations at INHSU 2026. Access the full INHSU 2026 conference program

Comprehensive support for malaria control and elimination in Nigeria. September 18, 2026 by PATH PATH Malaria supports locally led solutions across Nigeria, working with the government to strengthen programs and achieve lasting impact. Nigeria bears one of the world's highest malaria burdens, making its efforts to treat and prevent malaria critical in the global fight against the deadly disease. The country is meeting this challenge with evidence-supported interventions and a comprehensive national strategy geared toward reducing malaria incidence and mortality, strengthening primary health care and reporting systems, and supporting the introduction and maintenance of high-quality drugs and diagnostics. PATH's malaria portfolio in Nigeria. PATH's malaria-related work in Nigeria connects product introduction, delivery at scale, federal strategy and financing, disease surveillance, primary health care integration, and regional manufacturing in support of Nigeria's national malaria goals. PATH's extensive scope is complemented by strong partnerships with Nigeria's state and national government agencies, including key partners like the National Malaria Elimination Program (NMEP), National Primary Health Care and Development Agency (NPHCDA), Ministry of Health, and the Nigerian Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC). PATH strives to uplift national and state priorities, aligning its work with the country's needs and supporting the government and ministry in executing their plans. Federal strategy, analytics, and financing support. The Gates Foundation-funded Malaria Control and Elimination Partnership in Africa (MACEPA) works with the NMEP to provide critical support to translate national priorities into actionable plans with measurable impact. Most recently, MACEPA supported the workshops for the Global Fund to Fight AIDS, Tuberculosis and Malaria Global Grant Cycle 8 application and National Malaria Strategic Plan. At these workshops, MACEPA presented data collected via DHIS2 - the country's health information database and system - to help the ministry and NMEP identify the country's greatest malaria-related health needs and refine the most cost-efficient course of action to address them. Delivery of malaria tools at scale. Under the Reaching Every At-Risk Community and Household with Malaria Services (REACH Malaria) project, with US government support, PATH provides preventative measures for malaria to children under five years of age and pregnant women, delivering treatment for uncomplicated malaria and ensuring high-quality diagnostic services in laboratories across Nigeria. With a focus on community health and service delivery for hard-to-reach populations, REACH works within communities and with community health workers to improve the quality and uptake of proven interventions like seasonal malaria chemoprevention - a preventative treatment for children at risk of severe malaria - and the prevention and treatment of malaria in pregnancy. PATH, with funding from GiveWell, also supported the introduction of the malaria vaccine in Bayelsa State, focusing on integrating it into routine processes and targeted campaigns. Introducing the vaccine also provided an opportunity to explore other ways to strengthen and integrate child health care delivery platforms. PATH works closely with the state to identify ways to deliver multiple health interventions - seasonal malaria chemoprevention, perennial malaria chemoprevention, and routine immunization - within one platform. PATH's work demonstrates that targeted investments in coordination, community engagement, supportive supervision, and data validation and use can improve both uptake and dose completion. Integrated community-based interventions and primary health care strengthening. Integrated community case management (iCCM) is a widely supported community-based intervention that trains and deploys community health workers to tackle childhood morbidity and mortality. Since 2024, PATH has worked closely with the NPHCDA on the Rotary Healthy Communities Challenge (RHCC) and REACH Malaria projects to deploy and strengthen iCCM in Akwa Ibom, Kebbi, Ebonyi, and Benue states and align community health worker training with the government's community health worker strategy. Community health workers are trained to educate community members on health matters and to diagnose, treat, and refer cases of malaria, diarrhea, and pneumonia - uplifting community health and strengthening the primary health care system on a local level. Regional manufacturing for malaria diagnostics. Through the Unitaid-supported Manufacturing to Accelerate Diagnostic Excellence in Africa (MADE) Project and in partnership with PVAC, PATH supports more resilient access to essential malaria commodities. Currently, the country is heavily reliant on imported diagnostic technologies, leaving the provision of key malaria diagnostics vulnerable to global supply chain disruptions. Nigeria can improve sustainable access to diagnostics through regional manufacturing. MADE is partnering with Codex, a diagnostics manufacturing company near Lagos, Nigeria, to provide funding and technical support to build capacity to produce quality-assured and affordable malaria diagnostics. The project is also working with PVAC to identify ways to coordinate health care-focused industrial policy to support regional manufacturing of malaria commodities, working to limit political barriers that can impact sustainability. PATH Nigeria staff are committed to excelling progress, supporting local leadership, and encouraging a collaborative and adaptive environment to respond to the country's needs. Passionate about their work, they work diligently across PATH projects and with other partners to achieve the greatest impact. "PATH Nigeria has deepened my appreciation for what thoughtful collaboration and mutual support can achieve. By aligning expertise and uniting around a shared purpose, we foster growth and turn bold ideas into practical solutions." - Nigeria Country Lead, Dr. Ayebatari Lawson PATH Malaria Strategy 2026-2030. Nigeria is an example of PATH's malaria value proposition in action: deep technical expertise, trusted government partnership, strong delivery platforms, product and market-shaping capabilities, and the ability to connect global innovation with country-led implementation. PATH's work in Nigeria also exemplifies the application of the PATH Malaria Strategy 2026-2030, demonstrating PATH's comprehensive approach to supporting countries in their malaria control and elimination goals.

PATH appoints Dr. Jeremy Farrar as Chief of Asia, Middle East, and Europe regional division. September 9, 2026 by PATH Geneva, Switzerland - PATH is pleased to announce the appointment of Dr. Jeremy Farrar, a globally recognized leader in public health and clinical medicine, as Chief of its Asia, Middle East, and Europe regional division. In this role, Dr. Farrar will join PATH's Executive Leadership Team and oversee the organization's work across a dynamic and critical set of regions central to advancing global health. He will join the organization on October 1 and be based in Geneva. Dr. Farrar brings decades of experience at the forefront of global health, including leadership roles as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Vietnam, Assistant Director-General at the World Health Organization (WHO), and Director of Wellcome. Throughout his career, he has led transformative efforts at the intersection of clinical research, public health, and innovation. His work has spanned infectious diseases, noncommunicable diseases, emerging health threats, pandemic preparedness, workforce development, and health systems strengthening to address some of the world's most pressing health challenges. At PATH, Dr. Farrar will lead the organization's work across Asia, the Middle East, and Europe, deepening partnerships with local communities, governments, multilateral organizations, academic institutions, private-sector organizations, and philanthropic partners to advance sustainable health solutions. He will work closely with PATH's country and regional teams to support locally driven priorities and strengthen collaboration across the region. "Joining PATH at this moment is a very exciting opportunity," said Dr. Farrar. "For nearly 50 years, PATH has been recognized for bringing scientific excellence to some of the most complex health challenges facing communities that have too often been overlooked. This is a pivotal moment for global health, and an important moment to sharpen how innovation is translated into public health impact. Doing so will require us to address today's challenges with both urgency and ambition, anticipating and preparing for future changes in national and global health, and ensuring broader access to science and innovation. I look forward to contributing to that effort." PATH President and CEO Nikolaj Gilbert welcomed the appointment as a key step in advancing the organization's strategic priorities. "Jeremy is an exceptional leader, and we're very pleased to welcome him to PATH," said Gilbert. "He brings deep scientific expertise and a strong track record of working in partnership to address complex health challenges. In addition to his many professional achievements, he possesses deep knowledge of the realities that prevent access, the people that make health care possible, and the need for PATH's mission of ensuring breakthrough innovations reach all who need them." Dr. Farrar's appointment strengthens PATH's ability to translate innovation into public health impact in close partnership with the communities and health systems they are designed to serve. He will lead efforts to deepen regional connections, ensuring that solutions are not only scientifically robust, but also relevant, accessible, and impactful where they are needed most. Notes to editors For all media inquiries and interview requests: Lauren Grella, Senior Director Marketing and Communications, PATH, [email protected] About PATH PATH is a global nonprofit advancing health innovations for the people who need them most. With nearly 50 years of experience, a global team of experts, and trusted partnerships spanning 70+ countries, PATH turns breakthroughs into better health for millions every single year.